Clinical Trial Update: Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients [Phase 3]

View source ↗

Summary

Sanofi reports the completion of a Phase 3 trial evaluating two titration algorithms for insulin glargine 300 units/mL in adults with Type 2 Diabetes Mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• TOUJEO (insulin glargine)

Snippet

Sponsor: Sanofi | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED